Fineline Cube

Follow:
14499 Articles
JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025
CompanyDrug

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025

Hansoh Pharma's Almonertinib Approved in UK for EGFR-Mutated NSCLC
CompanyDrug

Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years
CompanyMedical Device

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025
CompanyDrug

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025

EU Approves Pfizer and Takeda's Adcetris in Hodgkin Lymphoma Combination Regimen
CompanyDrug

EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer
CompanyDrug

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline
CompanyDeals

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline

BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors
CompanyDeals

BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors

Harbin Pharma Agrees to Acquire Clinical Approval for Jesduvroq from Bocimed
CompanyDeals

Harbin Pharma Agrees to Acquire Clinical Approval for Jesduvroq from Bocimed

Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025
CompanyDrug

Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
CompanyDrug

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes